NL-OMON47725
已完成
3 期
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer * (KEYNOTE-355) - MK3475-355
Merck Sharp & Dohme (MSD)0 个研究点目标入组 12 人待定
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Merck Sharp & Dohme (MSD)
- 入组人数
- 12
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Have signed informed consent to study participation. The subject may also provide consent for Future Biomedical Research (FBR). However, the subject may participate in the main trial without participating in FBR.
- •2\. Be at least 18 years of age on the day of signing informed consent.
- •3\.Have locally recurrent inoperable breast cancer not previously treated with chemotherapy and which cannot be treated with curative intent.
- •Have metastatic breast cancer not previously treated with chemotherapy.
- •Note: Subjects with a history of locally recurrent breast cancer, which was previously treated with curative intent, may be eligible.
- •4\.Have centrally confirmed TNBC, as defined by the most recent ASCO/CAP guidelines.
- •Note: Subjects initially diagnosed with hormone receptor\*positive and/or HER2 positive breast cancer must have central confirmation of TNBC in a tumor biopsy obtained from a local recurrence or distant metastasis site.
- •5\.Have completed treatment for Stage I\-III breast cancer, if indicated, and \*6 months elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence.
- •Note: Adjuvant radiation therapy is not considered treatment with curative intent for the purpose of calculating the \*6 month interval requirement described above.
- •Note: First documentation of local or distant disease recurrence must be in the form of a dated biopsy, pathology, or imaging study report. A laboratory report indicating tumor marker elevation cannot be used as documentation of local or distant disease recurrence, unless accompanied by dated biopsy, pathology, or imaging study report.
排除标准
- •1\.Is currently participating in a clinical study and receiving an investigational agent and/or using an investigational device, or has participated in a clinical study and received an investigational agent and/or used an investigational device within 4 weeks prior to randomization.
- •Note: Subjects who have entered the follow\-up phase of a clinical study may participate as long as 4 weeks have elapsed since the last dose of the investigational agent and/or removal of the device.
- •Note: Subjects who were treated with radiation therapy may participate as long as at least 2 weeks have elapsed since the last dose of radiation therapy was administered.
- •2\.Has not recovered (e.g., to \*Grade 1 or to baseline) from AEs due to a previously administered therapy.
- •Note: Alopecia of any grade is an exception to this criterion.
- •Note: Prior to randomization, the subject must have recovered adequately from any toxicity and/or complications associated with any recent procedure.
- •3\.Has neuropathy \*Grade 2\.
- •4\.Has an active autoimmune disease that has required systemic treatment in the past 2 years (e.g., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
- •5\.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.
- •6\.Has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, and in situ cervical cancer.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerHigh-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast CancerMedDRA version: 20.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-004869-27-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerEUCTR2016-001432-35-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858
进行中（未招募）
1 期
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerEUCTR2017-004869-27-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerEUCTR2016-001432-35-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerEUCTR2016-001432-35-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858